PAVmed Secures $7 Million Convertible Note Financing
August 06, 2020 09:27 ET
|
PAVmed Inc.
NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVmed Subsidiary Lucid Diagnostics Receives Preliminary Payment Determination for EsoGuard™ Esophageal DNA Test
June 11, 2020 09:30 ET
|
PAVmed Inc.
NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its...
PAVmed to Hold Business Update Conference Call on May 21, 2020
May 11, 2020 09:30 ET
|
PAVmed Inc.
NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...
PAVmed to Hold Business Update Conference Call on April 9, 2020
March 24, 2020 09:30 ET
|
PAVmed Inc.
NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...
PAVmed Announces FDA 510(k) Re-submission for its CarpX™ Minimally Invasive Carpal Tunnel Device
March 09, 2020 09:30 ET
|
PAVmed Inc.
Incorporates data from successful clinical safety study in which all patients met pre-specified safety and effectiveness endpoints NEW YORK, March 09, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq:...
PAVmed Subsidiary Lucid Diagnostics Partners with Fred Hutchinson Cancer Research Center to Evaluate Barrett’s Esophagus (BE) Progression Biomarkers Using EsoCheck™
February 20, 2020 09:30 ET
|
PAVmed Inc.
Lucid secures exclusive option to license biomarker technology to detect progression from nondysplastic to dysplastic BE using EsoCheck to allow curative ablation before deadly esophageal cancer...
PAVmed Receives Formal Notification of Nasdaq Continued Listing Compliance
January 13, 2020 09:30 ET
|
PAVmed Inc.
NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has...
PAVmed Announces First Human CarpX™ Procedures
May 20, 2019 09:30 ET
|
PAVmed Inc.
First nine patients undergo successful CarpX procedures as part of FIH clinical safety study NEW YORK, May 20, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or...
PAVmed to Hold Business Update Conference Call on May 21, 2019
May 06, 2019 09:30 ET
|
PAVmed Inc.
NEW YORK, May 06, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...
PAVmed to Hold Business Update Conference Call on April 4, 2019
March 21, 2019 07:30 ET
|
PAVmed Inc.
NEW YORK, March 21, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...